Skip to main content
. 2018 Feb 26;9(21):15658–15672. doi: 10.18632/oncotarget.24585

Figure 5. Ribociclib decreases pRb, ATR, and Chk1 alone and in combination with cisplatin.

Figure 5

(i) Western blot evaluation and (ii) densitometric quantification of total Rb, p-Rb, p-Chk1, and p-ATR in Hey1 (A), COV504 (B), and PEO1 (C) cells after 72 hours of the indicated doses of Ribociclib or a single dose of cisplatin followed by three days of Ribociclib. Gels have been cropped for clarity. All samples were analyzed in triplicate with each experiment replicated at least once for each cell line.